Overview

Demoxytocin (desamino-oxytocin) is a synthetic peptide analog of oxytocin, the naturally occurring neurohormone produced by the hypothalamus and released by the posterior pituitary gland. Unlike native oxytocin, which is rapidly degraded in the gastrointestinal tract and must be administered parenterally, demoxytocin was specifically engineered with a desamino modification at position 1 that confers resistance to enzymatic degradation, enabling buccal (sublingual) or oral administration.

Clinically, demoxytocin has been used primarily in obstetric and gynecological settings. Its primary indications include the induction of labor at term, augmentation of stalled labor, and stimulation of milk ejection (let-down reflex) in breastfeeding women experiencing lactation difficulties. By binding to oxytocin receptors in the myometrium and mammary gland myoepithelial cells, it produces uterine contractions and milk release in a dose-dependent manner.

Demoxytocin represented a significant pharmacological advancement by providing a non-injectable route for oxytocin-like effects, improving patient compliance and enabling outpatient use. It is typically administered as buccal tablets, where it is absorbed through the oral mucosa. While its use has declined in some regions with the availability of other labor induction agents such as misoprostol and synthetic oxytocin infusions, it remains available in several countries and continues to be studied for potential applications beyond obstetrics.

Mechanism of Action

"

Oxytocin Receptor Agonism\n\nDemoxytocin (1-deamino-1-monocarba-oxytocin) is a synthetic cyclic nonapeptide analog of oxytocin with enhanced oral bioavailability and prolonged half-life due to the deamination of the cysteine-1 residue, which confers resistance to aminopeptidase degradation. It acts as a full agonist at the oxytocin receptor (OXTR), a Gq/11-coupled GPCR expressed in uterine myometrium, mammary myoepithelial cells, and various CNS regions (PMID: 3279827).\n\n

Uterotonic Signaling Cascade\n\nUpon binding OXTR in myometrial cells, demoxytocin activates phospholipase C-beta (PLCb), generating inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers calcium release from sarcoplasmic reticulum stores via IP3 receptors, while DAG activates protein kinase C (PKC). The resulting rise in intracellular calcium activates calmodulin-dependent myosin light chain kinase (MLCK), initiating actin-myosin cross-bridge cycling and uterine smooth muscle contraction (PMID: 16632900).\n\n

Lactation & Milk Ejection\n\nIn mammary tissue, demoxytocin stimulates contraction of myoepithelial cells surrounding the alveoli and ducts, facilitating milk ejection. The buccal/sublingual route of administration allows rapid onset while bypassing first-pass hepatic metabolism and gastrointestinal peptidase degradation (PMID: 6373779).\n\n

Pharmacokinetic Advantages\n\nThe deamino modification at position 1 extends the plasma half-life from approximately 3-5 minutes (native oxytocin) to 20-30 minutes, enabling practical oral or buccal dosing. Demoxytocin retains uterotonic and galactogenic potency comparable to native oxytocin while showing minimal vasopressin V2 receptor cross-reactivity, reducing antidiuretic side effects."

Reconstitution Calculator

Research

Safety Profile

Safety Profile: Demoxytocin

Common Side Effects

• Uterine cramping and discomfort (dose-dependent)
• Nausea and vomiting
• Headache
• Transient hypertension or hypotension
• Local irritation of buccal mucosa (with sublingual/buccal tablets)
• Breast engorgement and tenderness
• Mild diarrhea

Serious Adverse Effects

• Uterine hyperstimulation: Tetanic contractions that may compromise fetal blood supply (when used in labor)
• Uterine rupture: Particularly in women with prior cesarean section or uterine surgery
• Water intoxication/hyponatremia: Oxytocin analogs have antidiuretic properties; risk increases with prolonged use and IV fluid administration
• Fetal distress: Secondary to uterine hyperstimulation
• Anaphylaxis: Rare but documented with oxytocin analogs
• Neonatal hyperbilirubinemia: With peripartum use
• Cardiovascular events: Arrhythmias, myocardial ischemia (rare, primarily at high doses)

Contraindications

• Cephalopelvic disproportion or obstructed labor
• Fetal malpresentation (transverse lie, etc.)
• Placenta previa or vasa previa
• Prior classical cesarean section or significant uterine surgery
• Grand multiparity (high parity increases uterine rupture risk)
• Active genital herpes infection (when used for labor)
• Hypersensitivity to oxytocin or demoxytocin

Drug Interactions

• Prostaglandins (misoprostol, dinoprostone): Additive uterine stimulation — severe hyperstimulation risk
• Vasoconstrictors/Sympathomimetics: Potentiated hypertensive response
• Inhaled anesthetics (halothane, sevoflurane): May reduce oxytocic effect and increase hypotension risk
• Caudal/Epidural anesthesia with vasoconstrictors: Severe hypertension possible
• SSRIs: May enhance oxytocin effects (serotonin-oxytocin pathway interaction)
• Diuretics: Counter the antidiuretic effect; electrolyte monitoring advised

Population-Specific Considerations

• Postpartum women (lactation): Primary use case; generally well-tolerated at recommended doses
• Labor induction: Requires continuous fetal monitoring and careful dose titration
• Pre-eclampsia/Hypertension: Use with extreme caution — fluid balance and BP monitoring essential
• Renal impairment: Increased risk of water retention and hyponatremia
• Cardiovascular disease: Risk of arrhythmia; weigh benefits vs. risks carefully

Pharmacokinetic Profile